OBJECTIVES: Peroxisome assembly disorders are genetic disorders characterized by biochemical abnormalities, including low docosahexaenoic acid (DHA). The objective was to assess whether treatment with DHA supplementation would improve biochemical abnormalities, visual function, and growth in affected individuals. METHODS: This was a randomized, double-blind, placebo-controlled trial conducted at a single center. Treatment groups received supplements of DHA (100 mg/kg per day). The primary outcome measures were the change from baseline in the visual function and physical growth during the 1 year follow-up period. RESULTS:Fifty individuals were enrolled and randomized. Two were subsequently excluded from study analysis when it was determined that they had a single enzyme disorder of peroxisomal beta oxidation. Thirty-four returned for follow-up. Nine patients died during the trial of their disorder, and 5 others were lost to follow-up. DHA supplementation was well tolerated. There was no difference in the outcomes between the treated and untreated groups in biochemical function, electroretinogram, or growth. Improvements were seen in both groups in certain individuals. CONCLUSIONS:DHA supplementation did not improve the visual function or growth of treated individuals with peroxisome assembly disorders. CLASSIFICATION OF EVIDENCE: This interventional study provides Class II evidence that DHA supplementation did not improve the visual function or growth of treated individuals with peroxisome assembly disorders during an average of 1 year of follow-up in patients aged 1 to 144 months.
RCT Entities:
OBJECTIVES: Peroxisome assembly disorders are genetic disorders characterized by biochemical abnormalities, including low docosahexaenoic acid (DHA). The objective was to assess whether treatment with DHA supplementation would improve biochemical abnormalities, visual function, and growth in affected individuals. METHODS: This was a randomized, double-blind, placebo-controlled trial conducted at a single center. Treatment groups received supplements of DHA (100 mg/kg per day). The primary outcome measures were the change from baseline in the visual function and physical growth during the 1 year follow-up period. RESULTS: Fifty individuals were enrolled and randomized. Two were subsequently excluded from study analysis when it was determined that they had a single enzyme disorder of peroxisomal beta oxidation. Thirty-four returned for follow-up. Nine patients died during the trial of their disorder, and 5 others were lost to follow-up. DHA supplementation was well tolerated. There was no difference in the outcomes between the treated and untreated groups in biochemical function, electroretinogram, or growth. Improvements were seen in both groups in certain individuals. CONCLUSIONS:DHA supplementation did not improve the visual function or growth of treated individuals with peroxisome assembly disorders. CLASSIFICATION OF EVIDENCE: This interventional study provides Class II evidence that DHA supplementation did not improve the visual function or growth of treated individuals with peroxisome assembly disorders during an average of 1 year of follow-up in patients aged 1 to 144 months.
Authors: S Goldfischer; C L Moore; A B Johnson; A J Spiro; M P Valsamis; H K Wisniewski; R H Ritch; W T Norton; I Rapin; L M Gartner Journal: Science Date: 1973-10-05 Impact factor: 47.728
Authors: Nancy E Braverman; Gerald V Raymond; William B Rizzo; Ann B Moser; Mark E Wilkinson; Edwin M Stone; Steven J Steinberg; Michael F Wangler; Eric T Rush; Joseph G Hacia; Mousumi Bose Journal: Mol Genet Metab Date: 2015-12-23 Impact factor: 4.797
Authors: Milena Carvalho-Silva; Lara M Gomes; Maria L Gomes; Bruna K Ferreira; Patricia F Schuck; Gustavo C Ferreira; Felipe Dal-Pizzol; Jade de Oliveira; Giselli Scaini; Emilio L Streck Journal: Metab Brain Dis Date: 2019-04-04 Impact factor: 3.584
Authors: Dennis R Hoffman; Dianna K Hughbanks-Wheaton; N Shirlene Pearson; Gary E Fish; Rand Spencer; Alison Takacs; Martin Klein; Kirsten G Locke; David G Birch Journal: JAMA Ophthalmol Date: 2014-07 Impact factor: 7.389
Authors: Dianna K Hughbanks-Wheaton; David G Birch; Gary E Fish; Rand Spencer; N Shirlene Pearson; Alison Takacs; Dennis R Hoffman Journal: Invest Ophthalmol Vis Sci Date: 2014-07-11 Impact factor: 4.799
Authors: Rafaela Antonini; Giselli Scaini; Monique Michels; Mariane B D Matias; Patrícia F Schuck; Gustavo C Ferreira; Jade de Oliveira; Felipe Dal-Pizzol; Emilio L Streck Journal: Metab Brain Dis Date: 2019-12-11 Impact factor: 3.584
Authors: Femke C C Klouwer; Kevin Berendse; Sacha Ferdinandusse; Ronald J A Wanders; Marc Engelen; Bwee Tien Poll-The Journal: Orphanet J Rare Dis Date: 2015-12-01 Impact factor: 4.123
Authors: Malena Daich Varela; Priyam Jani; Wadih M Zein; Precilla D'Souza; Lynne Wolfe; Jennifer Chisholm; Christopher Zalewski; David Adams; Blake M Warner; Laryssa A Huryn; Robert B Hufnagel Journal: Am J Med Genet C Semin Med Genet Date: 2020-08-31 Impact factor: 3.359